IVF

INVO Fertility, Inc. (INVO Bioscience, Inc.) - 10-Q Summary

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for INVO Bioscience, Inc., a development-stage company focused on the INVOcell device and INVO procedure for infertility treatment. The report covers the three and nine-month periods ended September 30, 2010. The company is a smaller reporting company incorporated in Nevada. As of November 22, 2010, there were 65,903,206 shares of common stock outstanding.

Key Financial Metrics

Note: The Net Income for the nine months ended September 30, 2010, is primarily driven by a non-cash gain of $1,653,357 related to the change in fair value of derivative liabilities.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased by approximately 32% year-over-year ($38k vs $56k). Management attributed this to smaller international shipments and a September inventory shortage caused by cash constraints, which delayed fulfilling customer orders.
• Profitability Shift: The company reported a net income of $244,317 for the nine-month period, a significant turnaround from the $4.5 million net loss in the prior year. This is not due to operational profitability but rather a $1.65 million non-cash gain from the revaluation of derivative liabilities (warrants and convertible notes) due to the decline in the company's stock price.
• Expense Reduction: Operating expenses decreased by approximately $272,000 compared to the prior year, driven by a reduction in staff (from 7 to 5 employees), reduced travel costs, and deferred salaries.
• Liquidity Deterioration: Cash on hand dropped from $79,052 at the end of 2009 to $9,513 at September 30, 2010. The company paid off its $50,000 line of credit in August 2010.

Outlook, Risks, and Contingencies

• Going Concern: The filing explicitly states that the company's recurring losses, negative cash flows, and working capital deficiency raise substantial doubt about its ability to continue as a going concern. Continued operations depend on raising additional capital.
• Capital Needs: Management estimates a monthly burn rate of approximately $175,000. Without additional funding, the company may need to curtail spending and downsize operations further.
• Financing Activities: The company is utilizing a Reserve Equity Financing (REF) agreement with AGS Capital Group LLC to raise up to $10 million over two years. Small drawdowns have occurred, but significant capital remains needed.
• Regulatory Status: The company has CE marking for the European Economic Area and is pursuing FDA 510(k) clearance in the U.S., which requires a clinical trial estimated to cost $1 million. A grant application for this trial was unsuccessful.
• Legal Proceedings: A lawsuit filed in December 2009 by former employees of a predecessor company was dismissed by the Massachusetts Superior Court on November 12, 2010.
• Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of September 30, 2010, due to limited resources and a lack of segregation of duties.

Investor Verification Checklist

• Cash Runway: Verify the current cash balance and immediate ability to fund the estimated $175,000 monthly operating requirement.
• Derivative Liability Volatility: Understand that reported net income is heavily influenced by non-cash accounting adjustments related to stock price fluctuations, not operational cash generation.
• Capital Raise Progress: Confirm the status of the AGS Capital REF agreement and any new private placement efforts to fund the FDA clinical trial.
• Inventory and Sales Pipeline: Verify if the September inventory shortage has been resolved and if delayed orders have been shipped and recognized as revenue in subsequent periods.
• Debt Obligations: Review the terms of outstanding convertible notes and related party loans to assess immediate repayment risks.